

Johnson & Johnson Innovative Medicine Pipeline

Key Events in 2025*

POTENTIAL APPROVALS US/EU

✓ US EU	SIMPONI (golimumab) Pediatric Ulcerative Colitis (PURSUIT 2)	✓ US EU	IMAAVY (nipocalimab) Generalized Myasthenia Gravis (Vivacity MG3)
✓ EU	STELARA (ustekinumab) Pediatric Crohn's Disease (UNITI JR)	✓ US	SPRAVATO (esketamine) Treatment Resistant Depression monotherapy (TRD4005)
✓ US	TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)	US	CAPLYTA (lumateperone) Adjunctive Treatment for Major Depressive Disorder
✓ US ✓ EU	TREMFYA (guselkumab) Crohn's Disease Subcutaneous Induction (GRAVITI)	US ✓ EU	DARZALEX (daratumumab) Smoldering Multiple Myeloma (AQUILA)
✓ US	TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)	US ✓ EU	DARZALEX (daratumumab) Frontline multiple myeloma transplant ineligible (CEPHEUS)
✓ US	TREMFYA (guselkumab) Pediatric Juvenile Psoriatic Arthritis	✓ US	INLEXZO (gemcitabine intravesical system) Non Muscle Invasive Bladder Cancer (SunRISe-1)
✓ US ✓ EU	TREMFYA (guselkumab) Crohn's Disease (GALAXI)	US ✓ EU	RYBREVANT (amivantamab) Subcutaneous (PALOMA-3)
✓ EU	TREMFYA (guselkumab) Ulcerative Colitis (QUASAR)	EU	IMBRUVICA (ibrutinib) Frontline MCL (Triangle)
		✓ US	IMAAVY (nipocalimab) Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)

PLANNED SUBMISSIONS US/EU

US	nipocalimab Warm Autoimmune Hemolytic Anemia (ENERGY)	✓ US	INLEXZO (gemcitabine intravesical system) Non Muscle Invasive Bladder Cancer (SunRISe-1)
✓ EU	TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)	✓ US ✓ EU	AKEEGA (niraparib/abiraterone) M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)
✓ US	TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)		
✓ EU	TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)		
US EU	STELARA (ustekinumab) Pediatric Ulcerative Colitis (UNIFI JR)		
✓ US	STELARA (ustekinumab) Pediatric Crohn's Disease (UNITI JR)		
✓ US ✓ EU	icotrokinra Psoriasis (ICONIC)		

POTENTIAL CLINICAL DATA PRESENTATIONS'

Phase III	Phase I/ II
✓ AKEEGA (niraparib/abiraterone) M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)	✓ INLEXZO (gemcitabine intravesical system) Non Muscle Invasive Bladder Cancer (SunRISe-1)
✓ RYBREVANT / LAZCLUZE Non Small Cell Lung Cancer (MARIPOSA Final OS)	RYBREVANT (amivantamab) Head and Neck Cancer (ORIGAMI-4)
✓ TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)	✓ TALVEY + TECVAYLI Multiple Myeloma Relapsed/Refractory (RedirecTT-1)
✓ TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)	✓ JNJ-4496 Hematological Malignancies (LYM1001)
✓ TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)	✓ JNJ-5322 Multiple Myeloma (MMY1001)
✓ icotrokinra Psoriasis (ICONIC-LEAD)	✓ RYBREVANT (amivantamab) Colorectal Cancer (ORIGAMI-1 right-sided)
✓ icotrokinra Psoriasis (ICONIC-TOTAL)	✓ JNJ-8343 Prostate Cancer (PCR1001)
✓ icotrokinra Psoriasis (ICONIC-Advance1/2)	JNJ-4804 Co-antibody Therapy Psoriatic Arthritis (AFFINITY)
✓ aticaprant Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura 1)	✓ icotrokinra Ulcerative Colitis (ANTHEM)
✓ RPGR Gene Therapy Retinitis Pigmentosa (LUMEOS)	nipocalimab Combination Therapy Rheumatoid Arthritis (DAISY)

✓ = Achieved



1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of October 14, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.